Syn2bio S.A. (WSE:S2B)
Poland · Delayed Price · Currency is PLN 33.20
+0.20 (0.61%)
Last updated: May 21, 2026, 2:06 PM CET
Syn2bio Company Description
Syn2bio S.A., a biotechnology company, engages in the research and commercialization of Cardiac Marker, a radiopharmaceutical for diagnostic testing of heart disease in the field of myocardial perfusion.
The company’s flagship project is the cardiotracer project, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease.
Additionally, it operates The Centre for Research on New Compounds, a unit engaged in the search for new pharmaceutical compounds and their further study, registration, and market launch as a medicinal product.
Syn2bio S.A. was incorporated in 2025 and is based in Warsaw, Poland.
Syn2bio S.A.
| Country | Poland |
| Founded | 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Cezary Kozanecki |
Contact Details
Address: ul. Józefa Piusa Warsaw, 00-728 Poland | |
| Phone | 48 223 27 09 10 |
| Website | syn2bio.pl |
Stock Details
| Ticker Symbol | S2B |
| Exchange | Warsaw Stock Exchange |
| Reporting Currency | PLN |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Cezary Dariusz Kozanecki | Chief Executive Officer and Chairman of the Management Board |
| Anna Szymanska | Member of the Management Board |
| Sawa Zuzanna Zarebinska | Secretary and Member of the Supervisory Board |